Abstract:OBJECTIVE Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1) can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer (NSCLC) and their clinical significance by observing patient prognosis. METHODS VEGFR2 and NRP-1 were assessed by immunohistochemistry (IHC) in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor (KDR) and NRP-1 copy number gain (CNG) was assessed by fluorescence in situ hybridization (FISH). The distributions of overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared between groups by log-rank test. RESULTS Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG (+) were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue (χ(2)=11.22, P=0.001; χ(2)=9.82, P=0.001, respectively); similar results were obtained using CNGs (χ(2)=4.39, P=0.036; χ(2)=3.95, P=0.046, respectively). Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status (P<0.05), but not age, gender or pathology type (P>0.05). VEGFR2 showed a strong correlation with NRP-1 (Rs=0.68, P=0.00); similar results were observed with KDR and NRP-1 CNG (Rs=0.32, P=0.04). Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression (P<0.05). CONCLUSIONS According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis (P<0.05 for OS and PFS). This information will be beneficial for clinical anti-angiogenic treatment in NSCLC.

Association Between EGFR/KRAS Mutation and Expression of VEGFA, VEGFR and VEGFR2 in Lung Adenocarcinoma

Value of K-ras Gene Mutation and the Expression Ofvascular Endothelial Growth Factor on Lung Adenocarcinoma and the Association Between Them

Vegf-D Expression And Egfr Mutations In Non-Small-Cell Lung Carcinoma

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Clinical Outcome of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Therapy for Patients with Overlapping Kirsten Rat Sarcoma 2 Viral Oncogene Homolog and Epidermal Growth Factor Receptor Gene Mutations

Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma

Prognostic value of VEGFA and VEGFR2 in disease-free survival of patients with lung adenocarcinoma receiving surgery

Prognostic Analysis of Patients with Mutant and Wild-Type EGFR Gene Lung Adenocarcinoma

Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma

Cmar_a_200126 6139..6150

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer.

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.

Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma

Expression of Vascular Endothelial Cell Growth Factor and KDR Receptor in Gastric Adenocarcinoma and its Clinical Significance

Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Lung Adenocarcinomas

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation

Clinical significance of EGFR mutations in non-small cell lung cancer

Relationship Between Epidermal Growth Factor Receptor Mutations and CT Features in Patients with Lung Adenocarcinoma

TTF-1 and EGFR Expression Are Related to EGFR Mutation in Lung Adenocarcinoma

Expression of VEGFR2 and NRP-1 in Non-Small Cell Lung Cancer and Their Clinical Significance